FilingReader Intelligence
Anges and Boehringer Ingelheim begin HGF gene therapy manufacturing partnership
August 20, 2025 at 12:04 PM UTC•By FilingReader AI
Anges and Boehringer Ingelheim have signed a contract for development and manufacturing of HGF gene therapy's active pharmaceutical ingredient. The collaboration, spanning 20 years for clinical trial supplies, aims to accelerate regulatory approval.
Boehringer Ingelheim's BioXcellence will manufacture the active ingredient using proprietary microbial technology at their Vienna facility.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
TSE:4563•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Anges publishes news
Free account required • Unsubscribe anytime